A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 13,600 shares of DYN stock, worth $471,240. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,600
Previous 18,000 24.44%
Holding current value
$471,240
Previous $239,000 61.51%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$13.06 - $29.18 $57,464 - $128,392
-4,400 Reduced 24.44%
13,600 $386,000
Q4 2023

Feb 14, 2024

SELL
$6.62 - $13.64 $222,432 - $458,304
-33,600 Reduced 65.12%
18,000 $239,000
Q3 2023

Nov 14, 2023

SELL
$8.6 - $12.18 $939,980 - $1.33 Million
-109,300 Reduced 67.93%
51,600 $462,000
Q2 2023

Aug 14, 2023

SELL
$8.53 - $14.28 $644,868 - $1.08 Million
-75,600 Reduced 31.97%
160,900 $1.81 Million
Q1 2023

May 15, 2023

BUY
$10.88 - $15.0 $1.41 Million - $1.94 Million
129,200 Added 120.41%
236,500 $2.72 Million
Q4 2022

Feb 14, 2023

BUY
$9.37 - $13.8 $630,601 - $928,740
67,300 Added 168.25%
107,300 $1.24 Million
Q3 2022

Nov 14, 2022

BUY
$7.2 - $15.17 $113,040 - $238,169
15,700 Added 64.61%
40,000 $508,000
Q2 2022

Aug 15, 2022

SELL
$4.36 - $10.5 $105,512 - $254,100
-24,200 Reduced 49.9%
24,300 $167,000
Q1 2022

May 16, 2022

SELL
$6.52 - $12.27 $9,128 - $17,178
-1,400 Reduced 2.81%
48,500 $468,000
Q4 2021

Feb 14, 2022

BUY
$11.89 - $16.07 $267,525 - $361,575
22,500 Added 82.12%
49,900 $593,000
Q3 2021

Nov 15, 2021

BUY
$15.6 - $21.46 $23,400 - $32,190
1,500 Added 5.79%
27,400 $445,000
Q2 2021

Aug 16, 2021

SELL
$15.94 - $22.33 $165,776 - $232,231
-10,400 Reduced 28.65%
25,900 $545,000
Q1 2021

May 17, 2021

BUY
$14.0 - $29.3 $166,600 - $348,670
11,900 Added 48.77%
36,300 $564,000
Q4 2020

Feb 16, 2021

BUY
$16.81 - $23.94 $410,163 - $584,136
24,400 New
24,400 $512,000

Others Institutions Holding DYN

About Dyne Therapeutics, Inc.


  • Ticker DYN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,765,400
  • Market Cap $1.79B
  • Description
  • Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...
More about DYN
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.